Key result
SGLT2 inhibitors alter glycemic marker interpretation in T2D by increasing HGI and lowering GA/HbA1c.
Why the study?
Do SGLT2 inhibitors alter the interpretation of glycemic markers such as HbA1c and Glucose Management Indicator in people with Type 2 Diabetes?
Do SGLT2 inhibitors alter the interpretation of glycemic markers such as HbA1c and Glucose Management Indicator in people with Type 2 Diabetes?
SGLT2 inhibitors alter standard glycemic markers like HbA1c, highlighting the need for CGM-derived metrics for accurate glycemic assessment in patients with type 2 diabetes.
SGLT2i therapy alters the interpretation of glycemic markers by elevating HGI and lowering GA/HbA1c, independent of hematologic and renal factors. These findings emphasize the need for individualized assessment of glycemic control using CGM-derived metrics and complementary biomarkers.
No takes yet. Share an insight, caveat, or question.
Hayashi et al. (2026) studied this question. SGLT2 inhibitor therapy alters the interpretation of glycemic markers in type 2 diabetes by elevating HGI and lowering GA/HbA1c, independent of hematologic and renal factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: